Why Enanta Shares Are Plunging Today

Enanta Pharmaceuticals Inc's ENTA investigational COVID-19 pill, EDP-235, met its primary endpoints of safety and tolerability in its Phase 2 SPRINT trial but yielded mixed results on its effectiveness

A statistically significant improvement was observed with EDP-235 at 400mg at all time points in a prespecified population of patients enrolled within three days of symptom onset. 

While no difference was observed in time to the improvement of 14 targeted COVID-19 symptoms, an analysis of a subset of these symptoms showed a 2-day shorter time to improvement in patients receiving EDP-235 400mg enrolled within 3 days of symptom onset.

No effect on virologic endpoints as measured in the nose was detected due to the rapid viral decline in the placebo arm of this highly immunologically-experienced, standard-risk population.

Enanta is now looking for a partner to conduct a Phase 3 study or run another Phase II study in acute or long Covid.

The company had a net loss of $37.7 million in the first quarter of 2023, $4.1 million more than in the same period last year

Enanta said it had $225.1 million on hand at the end of March, excluding the April 2023 sale of 54.5% of its ongoing MAVYRET/MAVIRET royalties from AbbVie Inc ABBV for an upfront payment of $200 million.

Enanta has enough funds to support operations into 2026.

Price Action: ENTA shares are down 27.80% at $24.80 on the last check Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!